Company Overview
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants specifically utilized in the field of vascular surgery across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates within the Healthcare sector, focusing on the Medical Instruments & Supplies industry, which characterizes its role in providing critical tools and implants for surgical reconstruction. As of the latest reporting period, the firm maintains a market capitalization of $2.43B and generates annual revenue of $249.60M while employing 646 individuals globally. These financial figures indicate that LeMaitre Vascular is a substantial entity within its niche, possessing significant operational scale and a robust presence in international markets. The substantial market cap relative to its revenue suggests a high market multiple that investors associate with stable cash flow generation and a dominant position in specialized medical device distribution.
Financial Health
The company reported a trailing twelve-month revenue of $249.60M, with a corresponding net income of $57.73M and EBITDA of $73.53M. The gap between revenue and net income reveals a cost structure where the company retains approximately 23.1% of sales as profit after all expenses, including taxes and interest, are deducted. Free cash flow stands at $47.35M, indicating that the business generates substantial liquidity after capital expenditures, which provides significant financial flexibility for debt repayment, share buybacks, or organic expansion. Margins are robust across the board, with a gross margin of 70.4%, an operating margin of 21.8%, and a profit margin of 23.1%, each figure reflecting efficient production and pricing power in a competitive medical supply chain. Regarding leverage, the company holds $359.12M in cash against $185.59M in debt, resulting in a debt-to-equity ratio of 47.16, which suggests a balance sheet that is conservatively managed with ample cash reserves to cover obligations. Liquidity is exceptionally strong as evidenced by a current ratio of 12.89, indicating that current assets vastly exceed current liabilities and the company faces minimal risk of short-term insolvency. Management effectiveness is further highlighted by a Return on Equity of 15.8% and a Return on Assets of 6.8%, metrics that demonstrate the firm's ability to generate returns significantly above the cost of capital while utilizing its asset base efficiently.
Valuation Assessment
Valuation multiples for LeMaitre Vascular show a Trailing Twelve Month P/E Ratio of 42.31 compared to a Forward P/E of 33.77, implying that the market expects earnings growth to eventually bring the multiple down from current levels. The Price to Book ratio is recorded at 6.17, indicating that the market prices the company at a significant premium over its net asset value, likely due to the intangible value of its proprietary technology and brand reputation. Alternative valuation metrics include a Price to Sales ratio of 9.73 and an EV/EBITDA of 30.67, which suggest that investors are willing to pay a high multiple for sales and earnings given the company's consistent profitability and growth trajectory. Price metrics over the last year show a 52-Week High of $115.33 and a 52-Week Low of $71.42, placing the current trading range within a band that reflects recent volatility but remains anchored by strong fundamentals. The Beta value is 0.68, which means the stock's price volatility is historically less than the broader market, offering a potentially lower-risk profile relative to the overall equity market index.
Growth & Income
Recent performance data indicates a Revenue Growth of 15.7% year-over-year and an Earnings Growth of 41.4% year-over-year. Earnings are growing at a significantly faster rate than revenue, which implies that the company is benefiting from operational leverage, improved margin expansion, or pricing power that enhances profitability disproportionately to top-line growth. The company offers a Dividend Yield of 0.9% with a Payout Ratio of 31.8%, indicating that the payout is well below the earnings threshold and appears sustainable given the high growth in net income. The low payout ratio combined with high cash flow suggests that the company retains a majority of its earnings to reinvest in R&D and manufacturing capacity rather than distributing all profits to shareholders. Overall, the growth and income profile presents a hybrid characteristic where the stock supports modest dividend income while delivering accelerated earnings expansion that outpaces sales growth.